CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 103 enrolled
Drug / intervention
Valacyclovir +1 moredrug
Likely dose
Valacyclovir 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00803543
NCT00803543N/ACompleted
CompareCT.gov

Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daiy Valacyclovir in the Reduction of HSV-2 Recurrences and Viral Shedding

University of Alabama at Birmingham·interventional·Posted Dec 5, 2008·Updated Jul 13, 2017

In Brief

A clinical study evaluating Valacyclovir and Placebo for HIV and HIV Infections. Completed, enrolled 103 participants across 1 site.

Detailed Summary

The purpose of the study is to determine how common herpes is among persons with HIV who do not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in the blood, and the amount of HSV in bodily secretions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV, HIV Infections
CountriesUnited States
CollaboratorsGlaxoSmithKline

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 5, 2008
Enrollment StartJan 1, 2009
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.6 years ago

Interventions

Valacyclovirdrug

500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks

Placebodrug

Dosage: Two tablets once a day for 24 weeks